Vyvanse generic
Vyvanse is a prescription medicine used for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and is owned by Takeda Pharmaceuticals. It contains the active ingredient lisdexamfetamine dimesylate. It was first authorized for medical use in 2007. The ADHD drugs market is projected to reach US$ 16 billion in 2023. There were 36 drug patents protecting Vyvanse in United States, but as of now all of those patents have expired.
When will Vyvanse generic be available?
Vyvanse (lisdexamfetamine dimesylate) currently had patent protection until August 24, 2023. This means Vyvanse generic become available in the market after August 24, 2023, unless a Paragraph IV certification was filed challenging the patents before expiration.
Vyvanse uses
Vyvanse is approved to treat attention deficit hyperactivity disorder (ADHD) in patients aged 6 years and above. The active ingredient in Vyvanse, lisdexamfetamine dimesylate, is a stimulant that works by increasing levels of dopamine and norepinephrine in the brain to improve focus and attention.
Vyvanse patent expiration
Vyvanse currently has 39 patents covering the active ingredient, formulation, dosage, and methods of delivery that expired in February and August 2023. With patent expiration in 2023, Vyvanse generic can now enter the market and compete. Below is the list of recent Vyvanse patent expiration -